Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies

David G. Bostwick, Thomas M. Wheeler, Michael Blute, David M. Barrett, Gregory T. MacLennan, Thomas J. Sebo, Peter T. Scardino, Peter A. Humphrey, M'liss A. Hudson, Yves Fradet, Gary J. Miller, E. David Crawford, Brent A. Blumenstein, Howard E. Mahran, Brian J. Miles

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Objectives. Clinical staging of prostate cancer is inaccurate, often with significant upstaging on final pathologic review. We previously demonstrated the ability to predict extraprostatic extension of cancer by use of the Gleason score and serum prostate-specific antigen (PSA) measurements. Herein we present an interim analysis of data from an ongoing multi- institutional study to determine the predictive power of an enhancement of microvessel density analysis in combination with Gleason score and serum PSA to predict extraprostatic extension. Methods. We evaluated a total of 186 randomly selected needle biopsy samples and matched totally embedded radical prostatectomy samples with preoperative PSA concentrations and patient demographics. Gleason score and optimized microvessel density (OMVD) were determined from the needle biopsy samples; pathologic stage was verified by independent review of the radical prostatectomy samples. An automated digital image analysis system measured microvessel morphology and calculated the OMVD in the biopsy samples (Biostage; Bard Diagnostic Sciences, Seattle, Wash). Results. Prediction of extraprostatic extension was increased significantly when OMVD analysis was added to Gleason score and serum PSA concentration (P = 0.003). Conclusions. Optimized microvessel density analysis significantly increases the ability to predict extraprostatic extension of cancer preoperatively when combined with Gleason score and serum PSA concentration. This method appears to be a useful tool that can assist with treatment decisions in selected patients.

Original languageEnglish (US)
Pages (from-to)47-57
Number of pages11
JournalUrology
Volume48
Issue number1
DOIs
StatePublished - Jul 1996
Externally publishedYes

Fingerprint

Needle Biopsy
Microvessels
Neoplasm Grading
Prostate-Specific Antigen
Prostatic Neoplasms
Prostatectomy
Serum
Neoplasms
Demography
Biopsy

ASJC Scopus subject areas

  • Urology

Cite this

Bostwick, D. G., Wheeler, T. M., Blute, M., Barrett, D. M., MacLennan, G. T., Sebo, T. J., ... Miles, B. J. (1996). Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology, 48(1), 47-57. https://doi.org/10.1016/S0090-4295(96)00149-5

Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. / Bostwick, David G.; Wheeler, Thomas M.; Blute, Michael; Barrett, David M.; MacLennan, Gregory T.; Sebo, Thomas J.; Scardino, Peter T.; Humphrey, Peter A.; Hudson, M'liss A.; Fradet, Yves; Miller, Gary J.; Crawford, E. David; Blumenstein, Brent A.; Mahran, Howard E.; Miles, Brian J.

In: Urology, Vol. 48, No. 1, 07.1996, p. 47-57.

Research output: Contribution to journalArticle

Bostwick, DG, Wheeler, TM, Blute, M, Barrett, DM, MacLennan, GT, Sebo, TJ, Scardino, PT, Humphrey, PA, Hudson, MA, Fradet, Y, Miller, GJ, Crawford, ED, Blumenstein, BA, Mahran, HE & Miles, BJ 1996, 'Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies', Urology, vol. 48, no. 1, pp. 47-57. https://doi.org/10.1016/S0090-4295(96)00149-5
Bostwick, David G. ; Wheeler, Thomas M. ; Blute, Michael ; Barrett, David M. ; MacLennan, Gregory T. ; Sebo, Thomas J. ; Scardino, Peter T. ; Humphrey, Peter A. ; Hudson, M'liss A. ; Fradet, Yves ; Miller, Gary J. ; Crawford, E. David ; Blumenstein, Brent A. ; Mahran, Howard E. ; Miles, Brian J. / Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. In: Urology. 1996 ; Vol. 48, No. 1. pp. 47-57.
@article{5c87e8626f7544b693bd713e58ef598a,
title = "Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies",
abstract = "Objectives. Clinical staging of prostate cancer is inaccurate, often with significant upstaging on final pathologic review. We previously demonstrated the ability to predict extraprostatic extension of cancer by use of the Gleason score and serum prostate-specific antigen (PSA) measurements. Herein we present an interim analysis of data from an ongoing multi- institutional study to determine the predictive power of an enhancement of microvessel density analysis in combination with Gleason score and serum PSA to predict extraprostatic extension. Methods. We evaluated a total of 186 randomly selected needle biopsy samples and matched totally embedded radical prostatectomy samples with preoperative PSA concentrations and patient demographics. Gleason score and optimized microvessel density (OMVD) were determined from the needle biopsy samples; pathologic stage was verified by independent review of the radical prostatectomy samples. An automated digital image analysis system measured microvessel morphology and calculated the OMVD in the biopsy samples (Biostage; Bard Diagnostic Sciences, Seattle, Wash). Results. Prediction of extraprostatic extension was increased significantly when OMVD analysis was added to Gleason score and serum PSA concentration (P = 0.003). Conclusions. Optimized microvessel density analysis significantly increases the ability to predict extraprostatic extension of cancer preoperatively when combined with Gleason score and serum PSA concentration. This method appears to be a useful tool that can assist with treatment decisions in selected patients.",
author = "Bostwick, {David G.} and Wheeler, {Thomas M.} and Michael Blute and Barrett, {David M.} and MacLennan, {Gregory T.} and Sebo, {Thomas J.} and Scardino, {Peter T.} and Humphrey, {Peter A.} and Hudson, {M'liss A.} and Yves Fradet and Miller, {Gary J.} and Crawford, {E. David} and Blumenstein, {Brent A.} and Mahran, {Howard E.} and Miles, {Brian J.}",
year = "1996",
month = "7",
doi = "10.1016/S0090-4295(96)00149-5",
language = "English (US)",
volume = "48",
pages = "47--57",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies

AU - Bostwick, David G.

AU - Wheeler, Thomas M.

AU - Blute, Michael

AU - Barrett, David M.

AU - MacLennan, Gregory T.

AU - Sebo, Thomas J.

AU - Scardino, Peter T.

AU - Humphrey, Peter A.

AU - Hudson, M'liss A.

AU - Fradet, Yves

AU - Miller, Gary J.

AU - Crawford, E. David

AU - Blumenstein, Brent A.

AU - Mahran, Howard E.

AU - Miles, Brian J.

PY - 1996/7

Y1 - 1996/7

N2 - Objectives. Clinical staging of prostate cancer is inaccurate, often with significant upstaging on final pathologic review. We previously demonstrated the ability to predict extraprostatic extension of cancer by use of the Gleason score and serum prostate-specific antigen (PSA) measurements. Herein we present an interim analysis of data from an ongoing multi- institutional study to determine the predictive power of an enhancement of microvessel density analysis in combination with Gleason score and serum PSA to predict extraprostatic extension. Methods. We evaluated a total of 186 randomly selected needle biopsy samples and matched totally embedded radical prostatectomy samples with preoperative PSA concentrations and patient demographics. Gleason score and optimized microvessel density (OMVD) were determined from the needle biopsy samples; pathologic stage was verified by independent review of the radical prostatectomy samples. An automated digital image analysis system measured microvessel morphology and calculated the OMVD in the biopsy samples (Biostage; Bard Diagnostic Sciences, Seattle, Wash). Results. Prediction of extraprostatic extension was increased significantly when OMVD analysis was added to Gleason score and serum PSA concentration (P = 0.003). Conclusions. Optimized microvessel density analysis significantly increases the ability to predict extraprostatic extension of cancer preoperatively when combined with Gleason score and serum PSA concentration. This method appears to be a useful tool that can assist with treatment decisions in selected patients.

AB - Objectives. Clinical staging of prostate cancer is inaccurate, often with significant upstaging on final pathologic review. We previously demonstrated the ability to predict extraprostatic extension of cancer by use of the Gleason score and serum prostate-specific antigen (PSA) measurements. Herein we present an interim analysis of data from an ongoing multi- institutional study to determine the predictive power of an enhancement of microvessel density analysis in combination with Gleason score and serum PSA to predict extraprostatic extension. Methods. We evaluated a total of 186 randomly selected needle biopsy samples and matched totally embedded radical prostatectomy samples with preoperative PSA concentrations and patient demographics. Gleason score and optimized microvessel density (OMVD) were determined from the needle biopsy samples; pathologic stage was verified by independent review of the radical prostatectomy samples. An automated digital image analysis system measured microvessel morphology and calculated the OMVD in the biopsy samples (Biostage; Bard Diagnostic Sciences, Seattle, Wash). Results. Prediction of extraprostatic extension was increased significantly when OMVD analysis was added to Gleason score and serum PSA concentration (P = 0.003). Conclusions. Optimized microvessel density analysis significantly increases the ability to predict extraprostatic extension of cancer preoperatively when combined with Gleason score and serum PSA concentration. This method appears to be a useful tool that can assist with treatment decisions in selected patients.

UR - http://www.scopus.com/inward/record.url?scp=0030200923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030200923&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(96)00149-5

DO - 10.1016/S0090-4295(96)00149-5

M3 - Article

C2 - 8693651

AN - SCOPUS:0030200923

VL - 48

SP - 47

EP - 57

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -